Dizdarer 2000

Methods	Prospective quasi‐randomised, open‐label trial conducted at a single hospital in Turkey 2 treatment arms: CBZ and OXC
Participants	Children with partial epilepsy (not stated how many were newly diagnosed) Number randomised: CBZ = 26, OXC = 26 21 boys (40%) 100% of participants had partial epilepsy Mean age (range): 11 (4‐15 years)
Interventions	Monotherapy with CBZ or OXC CBZ prescribed at 20‐25 mg/kg/d and OXC at 30‐50 mg/kg/d Range of follow‐up: 3.5 to 26 months
Outcomes	Seizure recurrence Most common side effects Number of participants switching treatment
Notes	IPD provided for all outcomes of this review by trial author. Trial publication available as abstract only, additional data provided by trial authors
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Quasi‐randomisation by alternately allocating participants to CBZ or OXC (information provided by trial authors)
Allocation concealment (selection bias)	High risk	Allocation was not concealed (alternate allocation)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐ label trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐ label trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates reported, ITT approach, all randomised participants analysed from IPD provided (see footnote 2)
Selective reporting (reporting bias)	Low risk	All outcomes reported or calculated with IPD provided (see footnote 2)
Other bias	Low risk	None identified